It has been reported recently that FGFR3 mutations are frequently found in non‐CD8+ T‐cell‐inflamed MIBC, and it was proposed that the FGFR3 pathway could be targeted to overcome resistance and sensitise tumours to PD‐1/PD‐L1 immunotherapy 40. Here, CD274 is linked to neoplasm.